JP7372910B2 - ヒト多能性幹細胞由来の胸腺オルガノイドのインビトロ生成 - Google Patents

ヒト多能性幹細胞由来の胸腺オルガノイドのインビトロ生成 Download PDF

Info

Publication number
JP7372910B2
JP7372910B2 JP2020516436A JP2020516436A JP7372910B2 JP 7372910 B2 JP7372910 B2 JP 7372910B2 JP 2020516436 A JP2020516436 A JP 2020516436A JP 2020516436 A JP2020516436 A JP 2020516436A JP 7372910 B2 JP7372910 B2 JP 7372910B2
Authority
JP
Japan
Prior art keywords
cells
thymic
vitro
organoids
keratin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534004A5 (enExample
JP2020534004A (ja
Inventor
イー． ヴィズカルド、ラウル
ピー． レスティフォ、ニコラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2020534004A publication Critical patent/JP2020534004A/ja
Publication of JP2020534004A5 publication Critical patent/JP2020534004A5/ja
Application granted granted Critical
Publication of JP7372910B2 publication Critical patent/JP7372910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/065—Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020516436A 2017-09-20 2018-09-19 ヒト多能性幹細胞由来の胸腺オルガノイドのインビトロ生成 Active JP7372910B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560908P 2017-09-20 2017-09-20
US62/560,908 2017-09-20
PCT/US2018/051625 WO2019060336A1 (en) 2017-09-20 2018-09-19 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS

Publications (3)

Publication Number Publication Date
JP2020534004A JP2020534004A (ja) 2020-11-26
JP2020534004A5 JP2020534004A5 (enExample) 2021-11-04
JP7372910B2 true JP7372910B2 (ja) 2023-11-01

Family

ID=63794667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516436A Active JP7372910B2 (ja) 2017-09-20 2018-09-19 ヒト多能性幹細胞由来の胸腺オルガノイドのインビトロ生成

Country Status (4)

Country Link
US (1) US11898166B2 (enExample)
EP (1) EP3684920A1 (enExample)
JP (1) JP7372910B2 (enExample)
WO (1) WO2019060336A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025150823A1 (ko) * 2024-01-11 2025-07-17 재단법인 아산사회복지재단 흉선 세포 또는 흉선 상피세포를 유효성분으로 포함하는 암 예방용 약학적 조성물

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
NZ753051A (en) 2016-11-04 2023-03-31 Children’S Hospital Medical Center Liver organoid compositions and methods of making and using same
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
SG11202100533VA (en) 2018-07-26 2021-02-25 Childrens Hospital Med Ct Hepato-biliary-pancreatic tissues and methods of making same
SG11202102431YA (en) 2018-09-12 2021-04-29 Childrens Hospital Med Ct Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
EP3947639A4 (en) 2019-04-01 2023-01-25 The Trustees of Columbia University in the City of New York METHOD OF PROMOTING THYMICAL PITHELIAL CELL AND THYMAL PITHELIAL CELL PROGENITOR DIFFERENTIATION FROM PLURIPOTENTIC STEM CELLS
EP3959304A4 (en) * 2019-04-26 2023-01-25 The Regents Of The University Of Colorado, A Body Corporate GENERATION OF FUNCTIONAL AND PATIENT-SPECIFIC THYMUS TISSUE IN VIVO FROM INDUCED PLURIPOTENTS STEM CELLS
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
AU2020329194A1 (en) * 2019-08-13 2022-02-24 Children's Hospital Medical Center Improved methods for making organoid compositions
JP2023502522A (ja) * 2019-11-25 2023-01-24 アレゲーニー シンガー リサーチ インスティテュート ヒト多能性幹細胞からバイオエンジニアリングされた胸腺オルガノイド
JP2023524213A (ja) * 2020-04-28 2023-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビトロで胸腺細胞を生成するための方法
WO2022076751A1 (en) * 2020-10-07 2022-04-14 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and use for in vitro and in vivo generation of functional thymic tissue
GB2601793B (en) * 2020-12-10 2025-07-23 The Francis Crick Institute Ltd Thymic constructs and uses thereof
CA3234507A1 (en) * 2021-10-15 2023-04-20 Bing Lim Thymic cells and methods of making
JPWO2023243627A1 (enExample) * 2022-06-17 2023-12-21
CN119614476A (zh) * 2024-11-13 2025-03-14 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 胸腺类器官的构建方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143529A1 (ja) 2009-06-09 2010-12-16 国立大学法人名古屋大学 多能性幹細胞を胸腺上皮へ分化誘導する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
AU2008247311A1 (en) 2007-05-03 2008-11-13 Australian Stem Cell Centre Ltd. Novel thymic cellular populations and uses thereof
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2014066649A1 (en) 2012-10-26 2014-05-01 The Regents Of The University Of California A strategy for engineering various 3d tissues, organoids and vasculature
TW202344686A (zh) 2015-10-30 2023-11-16 美國加利福尼亞大學董事會 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143529A1 (ja) 2009-06-09 2010-12-16 国立大学法人名古屋大学 多能性幹細胞を胸腺上皮へ分化誘導する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mol. Ther.，2015年，Vol. 23, No. 7，p. 1262-1277

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025150823A1 (ko) * 2024-01-11 2025-07-17 재단법인 아산사회복지재단 흉선 세포 또는 흉선 상피세포를 유효성분으로 포함하는 암 예방용 약학적 조성물

Also Published As

Publication number Publication date
EP3684920A1 (en) 2020-07-29
US11898166B2 (en) 2024-02-13
JP2020534004A (ja) 2020-11-26
WO2019060336A1 (en) 2019-03-28
US20200270571A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP7372910B2 (ja) ヒト多能性幹細胞由来の胸腺オルガノイドのインビトロ生成
Roszell et al. Efficient derivation of alveolar type II cells from embryonic stem cells for in vivo application
AU2016216570B2 (en) Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes
JP4085062B2 (ja) 霊長類の胚性幹細胞から由来した内皮細胞
US8574567B2 (en) Multipotent stem cells and uses thereof
Sakurai et al. Paraxial mesodermal progenitors derived from mouse embryonic stem cells contribute to muscle regeneration via differentiation into muscle satellite cells
CN101962629B (zh) 肝脏前体细胞及其制备方法与应用
US11607429B2 (en) Derivation and self-renewal of ISI1+ cells and uses thereof
Wang et al. Derivation of smooth muscle cells with neural crest origin from human induced pluripotent stem cells
CN101962628B (zh) 肝脏内胚层细胞及其制备和纯化方法
US12037607B2 (en) Methods of preparing hematopoietic progenitor cells in vitro
US20060084167A1 (en) Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells
KR20110051166A (ko) 포유동물의 전구 세포를 인슐린 생성 이자섬 세포로 분화시키는 방법
US9598675B2 (en) Method for preparing mesenchymal stem cell-like cells and cardiomyocyte-like cells
JP2012165660A (ja) ヒト造血幹細胞を増幅させるための組成物及び方法
TW201734206A (zh) 高機能肝細胞及其利用
TW202204609A (zh) Ｔ前驅細胞的製造方法
Suzuki et al. GENETIC DISORDERS-DEVELOPMENT Platelet-derived growth factor plays a critical role to convert bone marrow cells into glomerular mesangial-like cells.

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231020

R150 Certificate of patent or registration of utility model

Ref document number: 7372910

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150